Latest news

• Sanofi gets cardio outcomes claim for Praluent in EU

  The two PCSK9 inhibitors are locked in a battle for the severe, high-risk end of the cholesterol market – mainly patients who are unable to control low-density lipoprotein (LDL) cholesterol ... Complicating the picture is a global intellectual property

• MS and cholesterol drugs picked for new UK rapid uptake push

  baby. PCSK9 inhibitors for treatment of primary hypercholesterolaemia and mixed dyslipidaemia  - Cost-effective drugs that significantly lower cholesterol.

• CETP inhibitor class finally dies as Merck abandons anacetrapib

  The drug follows in the footsteps of other CETP inhibitors - including Pfizer's torcetrapib, Roche's dalcetrapib and Eli Lilly's evacetrapib - although those candidates all failed to show a benefit ... In the interim almost all of those brands have

• Merck & Co's anacetrapib data fails to generate much excitement

  contend in the statin add-on market with PCSK9 inhibitors such as Amgen's Repatha, which showed a larger (15%) risk reduction in the FOURIER trial but are still struggling to ... If Merck does choose to abandon anacetrapib the drug will follow several

• Merck & Co's anacetrapib rescued by positive phase III trial

  cholesterol-lowering drugs now that the PCSK9 inhibitors - Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab) - are being used alongside statin therapy. ... CETP inhibitors are designed to increase levels of high-density